PBYI · Company research
PUMA BIOTECHNOLOGY INC (PBYI): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
19records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology | Zacks highlights four breast cancer drug stocks for Breast Cancer Awareness Month. AstraZeneca and Roche are established large-cap pharma companies with strong commercial portfolios and pipeline opportunities. Puma Biotechnology relies on Nerlynx sales with a mid-stage pipeline candidate. Olema Oncology is a clinical-stage company dependent on its lead candidate palazestrant's phase III trial results expected in Q1 2027. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 0.333 | 1 |
| Puma Biotechnology, Inc. (PBYI) Stock Price, News, Quote & History - Yahoo! Finance Canada | Puma Biotechnology, Inc. (PBYI) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| 4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month | Four pharmaceutical and biotech companies are positioned in the breast cancer treatment market with varying growth prospects. AstraZeneca and Roche leverage established drug portfolios with expanding indications, Puma Biotechnology focuses on Nerlynx sales growth, while Olema Oncology awaits pivotal clinical trial results for its lead candidate palazestrant expected in Q1 2027. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.667 | 1 |
| 4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month | Four pharmaceutical and biotech companies are positioned in the breast cancer treatment market with varying growth prospects. AstraZeneca and Roche leverage established drug portfolios with expanding indications, Puma Biotechnology focuses on Nerlynx sales growth, while Olema Oncology awaits pivotal clinical trial results for its lead candidate palazestrant expected in Q1 2027. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.667 | 1 |
| A CEO's $16-per-share warrant expired unexercised at Puma Biotechnology (PBYI). - Stock Titan | A CEO's $16-per-share warrant expired unexercised at Puma Biotechnology (PBYI). Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| Puma Biotechnology Inc (NASDAQ: PBYI) Share Price, PBYI Stock News, PBYI Share Price & Updates - Kalkine | Puma Biotechnology Inc (NASDAQ: PBYI) Share Price, PBYI Stock News, PBYI Share Price & Updates Kalkine | View source ↗ | Kalkine | Oct 2, 2026 | neutral | 0 | 0.6 |
| Puma Biotechnology Inc (NASDAQ: PBYI) Share Price, PBYI Stock News, PBYI Share Price & Updates - kalkine.ca | Puma Biotechnology Inc (NASDAQ: PBYI) Share Price, PBYI Stock News, PBYI Share Price & Updates kalkine.ca | View source ↗ | kalkine.ca | Sep 25, 2026 | neutral | 0 | 0.6 |
| About 50 patients with small cell lung cancer will join Puma's new trial. - Stock Titan | About 50 patients with small cell lung cancer will join Puma's new trial. Stock Titan | View source ↗ | Stock Titan | Sep 17, 2026 | neutral | 0 | 0.6 |
| Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise (NASDAQ:PBYI) - Seeking Alpha | Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise (NASDAQ:PBYI) Seeking Alpha | View source ↗ | Seeking Alpha | Sep 8, 2026 | neutral | 0 | 0.6 |
| Five new hires get awards tied to 33,550 Puma shares - Stock Titan | Five new hires get awards tied to 33,550 Puma shares Stock Titan | View source ↗ | Stock Titan | Sep 3, 2026 | neutral | 0 | 0.6 |
| (PBYI) Volatility Zones as Tactical Triggers - Stock Traders Daily | (PBYI) Volatility Zones as Tactical Triggers Stock Traders Daily | View source ↗ | Stock Traders Daily | Aug 28, 2026 | neutral | 0 | 0.6 |
| Is Puma Biotechnology (PBYI) a Great Value Stock Right Now? - Yahoo Finance | Is Puma Biotechnology (PBYI) a Great Value Stock Right Now? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 12, 2026 | neutral | 0 | 0.6 |
| Puma Biotechnology (PBYI) Stock Jumps On Profit Strength As Earnings Outlook Fades - Simply Wall Street | Puma Biotechnology (PBYI) Stock Jumps On Profit Strength As Earnings Outlook Fades Simply Wall Street | View source ↗ | Simply Wall Street | Aug 8, 2026 | neutral | 0 | 0.6 |
| Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why - TradingView | Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why TradingView | View source ↗ | TradingView | Jun 11, 2026 | neutral | 0 | 0.6 |
| There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings - Simply Wall Street | There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings Simply Wall Street | View source ↗ | Simply Wall Street | May 15, 2026 | neutral | 0 | 0.6 |
| Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00 - Yahoo Finance | Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00 Yahoo Finance | View source ↗ | Yahoo Finance | May 11, 2026 | neutral | 0 | 0.6 |
| PBYI Should I Buy - Intellectia AI | PBYI Should I Buy Intellectia AI | View source ↗ | Intellectia AI | Mar 21, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Apr 9, 2024 | neutral | 0 | 0.6 |
| PBYI Stock Price and Chart — NASDAQ:PBYI - TradingView | PBYI Stock Price and Chart — NASDAQ:PBYI TradingView | View source ↗ | TradingView | Jul 21, 2017 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.